Every 8-K that ICU Medical Inc (ICUI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ICUI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICUI filings page.
ICU Medical reported second quarter 2026 results and raised its full‑year 2026 outlook. GAAP revenue for the quarter was $551.7 million, up 1% year over year, while non-GAAP organic revenue grew 6%. GAAP gross margin improved to 43% from 38%. GAAP net income was $19.1 million, or $0.76 per diluted share, compared with $35.3 million, or $1.43, a year earlier, which included a gain on sale of business. Adjusted diluted EPS rose to $2.37 from $2.10 and Adjusted EBITDA increased to $110.0 million from $100.3 million.
Consumables revenue grew to $289.3 million and Infusion Systems to $189.0 million, while Vital Care declined to $73.4 million following the 2025 IV Solutions divestiture. For fiscal 2026, the company now guides GAAP net income to $73–$83 million and GAAP EPS to $2.89–$3.29. Adjusted EBITDA guidance increased to $415–$435 million and adjusted EPS to $8.60–$9.00. As of June 30, 2026, cash and cash equivalents were $298.3 million, with total debt of about $1.23 billion and a net leverage ratio of 2.28x.
ICU Medical, Inc. reported results from its 2026 annual stockholder meeting and related governance changes. Stockholders approved amendments to the Amended and Restated Certificate of Incorporation to replace certain supermajority requirements with simple majority voting and to grant stockholders owning at least 25% of voting power the right to call special meetings.
These Charter Amendments became effective when the amended charter was filed in Delaware, and the Board implemented conforming changes through Amended and Restated Bylaws, including detailed procedures and informational requirements for special meeting requests. All director nominees were elected, Deloitte & Touche LLP was ratified as auditor for the year ending December 31, 2026, and executive compensation was approved on an advisory basis.
Stockholders also approved an adjournment authority related to Proposal 5 if needed. An advisory stockholder proposal to establish a 10% stockholder special meeting right did not pass, leaving the new 25% ownership threshold as the governing standard for stockholder-called special meetings.
ICU Medical reported first quarter 2026 results reflecting its IV Solutions divestiture. GAAP revenue was $530.2 million, down 12% year-over-year, but non-GAAP organic revenue excluding the divested business and foreign currency increased 1%.
GAAP gross profit was $206.2 million with gross margin improving to 39% from 35%. The company generated GAAP net income of $30.1 million, or $1.20 per diluted share, versus a GAAP net loss of $15.5 million, or $(0.63) per diluted share, a year earlier. Adjusted diluted EPS rose to $1.97 from $1.72, and adjusted EBITDA was stable at $98.7 million. Free cash flow for the quarter was $27.6 million.
ICU Medical, Inc. reported that its Board’s Compensation Committee approved an amendment to the company’s Executive Severance Plan. The amendment, effective as of December 31, 2025, extends the plan’s expiration date by three years, from December 31, 2025 to December 31, 2028.
The Executive Severance Plan governs severance benefits for certain senior executives, so extending its term maintains the existing framework for executive departure protections. The full text of the Third Amendment to the Executive Severance Plan is provided as an exhibit and is incorporated by reference.
ICU Medical reported fourth quarter 2025 revenue of $540.7 million, down from $629.8 million a year earlier, mainly reflecting the prior divestiture of its IV Solutions business within the Vital Care line. Despite lower revenue, GAAP gross margin improved to 38% from 36%.
The company posted a GAAP net loss of $15.7 million, or $(0.64) per diluted share, narrowing from a $23.8 million loss in 2024. On a non-GAAP basis, adjusted EBITDA was $98.2 million and adjusted diluted EPS was $1.91, both below the prior year.
For full-year 2025, ICU Medical generated $2.23 billion in revenue and modest GAAP net income of $0.7 million, supported by a gain on a business sale and strong operating cash flow of $179.8 million. The company reduced long-term debt and ended the year with $308.0 million in cash.
Looking to fiscal 2026, management guides GAAP net income between $26 million and $44 million and GAAP EPS between $1.03 and $1.74. ICU Medical expects adjusted EBITDA of $400–$430 million and adjusted EPS of $7.75–$8.45, assuming continued non-GAAP adjustments for items like stock compensation, amortization, restructuring, and quality-related remediation.
ICU Medical, Inc. (ICUI) filed a Form 8-K to report that it furnished a press release announcing its financial results for the third quarter of 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference under Item 2.02 (Results of Operations and Financial Condition). The filing lists ICU Medical’s common stock on the Nasdaq Global Select Market under the symbol ICUI. This 8-K serves to make the company’s Q3 2025 results announcement available to the market via the furnished exhibit.